Shanghai Henlius Biotech (HKSE:02696) Long-Term Capital Lease Obligation : HK$178 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Long-Term Capital Lease Obligation?

Shanghai Henlius Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$178 Mil.

Shanghai Henlius Biotech's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (HK$222 Mil) to Dec. 2023 (HK$204 Mil) and declined from Dec. 2023 (HK$204 Mil) to Jun. 2024 (HK$178 Mil).

Shanghai Henlius Biotech's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (HK$268 Mil) to Dec. 2022 (HK$201 Mil) but then increased from Dec. 2022 (HK$201 Mil) to Dec. 2023 (HK$204 Mil).

Shanghai Henlius Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Shanghai Henlius Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Long-Term Capital Lease Obligation Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

156.58

261.90

267.62

200.61

203.94

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial													200.61	182.10	221.55	203.94	177.74

Shanghai Henlius Biotech (HKSE:02696) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Shanghai Henlius Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Qatar Investment Authority	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you
Jiang Wei-dong	2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc.	2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines